View in EDS

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.

Saved in:
Bibliographic Details
Title: Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.
Authors: Aizenbud L; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA., Schoenfeld DA; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA., Caulfield JI; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA., Mann JE; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA., Austin MR; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA., Perdigoto AL; Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USA., Herold KC; Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA., Kluger HM; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA Harriet.Kluger@Yale.edu.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jun; Vol. 11 (6).
Publication Type: Letter; Research Support, N.I.H., Extramural; Comment
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2023-007397